03/16/2026 09:08
Ant Group’s Robbyant Teams Up with Leju to Bridge Embodied Intelligence and Real-World Applications

Robbyant, an embodied AI company within Ant Group, today announced a strategic partnership with Leju Robot, a leading company focused on core robotic technologies. This partnership aims to drive innovation centered on embodiment, data, and models of robots, exploring the application and commercialization of embodied AI in real-world scenarios and accelerating the transformation of embodied AI robots from specific task execution to general intelligence. This press release features multimedia. V...

03/16/2026 10:00
Experian Marks a Breakthrough in Consumer AI with the Next Evolution of Its Virtual Assistant

Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™, a significant advancement in its Consumer First AI strategy that expands personalized, conversational financial guidance to millions of consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316538160/en/Experian today unveiled the next evolution of the Experian Virtual Assistant, EVA™. “This next generation of EVA reflects the direction of our...

03/24/2026 08:00
Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base

Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to e...

03/26/2026 15:05
EDB Redeems Five-Year Eurobonds in Full, Meeting all Obligations to Investors

The Eurasian Development Bank (EDB), a leading multilateral development bank fostering economic growth in the Eurasian region, has redeemed its five-year Eurobond issue (ISIN XS2315951041). The total amount paid to investors at redemption was 286 million euro, comprising the final coupon payment and repayment of the outstanding principal. The Eurobonds were originally issued under the Bank's EMTN Programme with a nominal issue size of 300 million euro. The bonds were listed on Euronext Dubl...

03/24/2026 08:20
Vonage and ServiceNow Expand their Partnership

Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptiona...

05/01/2026 21:28
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two ...

03/16/2026 10:53
Lebrikizumab Delivered Significant Skin Clearance and Improved Disease Severity in Children With Moderate-to-severe Atopic Dermatitis

Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and safety of lebrikizumab for children and adolescents with moderate-to-severe atopic dermatitis aged 6 months to <18 years. Lebrikizumab met both co-primary and key secondary endpoints, delivering near-complete skin clearance, reduced disease severity, itch relief and improved quality of life at Wee...

03/24/2026 08:30
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid...

03/16/2026 12:00
SBC Medical Announces Opening of Brand Flagship "NEO Skin Clinic Ginza."

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced that its specialized aesthetic brand, “NEO Skin Clinic,” will open its flagship location in Tokyo’s Ginza district, a globally recognized medical tourism hub and highly competitive district, on Saturday, March 28, 2026. This press release features multimedia. View the full release...